In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

LifeScan, Novo Nordisk develop diabetes devices

14 Jun 2001

Executive Summary

Johnson & Johnson subsidiary LifeScan (blood glucose monitoring systems) will work with Novo Nordisk (diabetes therapeutics) in a worldwide collaboration to develop and market diabetes management devices for diabetics administering insulin via daily injections.
Deal Industry
  • In Vitro Diagnostics
  • Medical Devices
    • Diagnostic Equipment & Supplies
  • In Vitro Diagnostics
    • Glucose Testing
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Marketing
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By